Zacks Research Has Bearish Forecast for Amgen Q2 Earnings

Amgen Inc. (NASDAQ:AMGN) – Equities researchers at Zacks Research lowered their Q2 2025 EPS estimates for Amgen in a report issued on Thursday, May 22nd. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $5.20 per share for the quarter, down from their prior estimate of $5.22. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.32 EPS, Q4 2025 earnings at $5.24 EPS, Q1 2026 earnings at $4.60 EPS, Q2 2026 earnings at $5.24 EPS, Q3 2026 earnings at $5.29 EPS, Q4 2026 earnings at $5.34 EPS and FY2026 earnings at $20.48 EPS.

Several other research firms have also recently weighed in on AMGN. Mizuho lifted their price target on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a report on Wednesday, May 7th. UBS Group reaffirmed a “neutral” rating and issued a $315.00 target price (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Royal Bank of Canada reduced their price target on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Piper Sandler lowered their price objective on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a report on Friday, May 16th. Finally, Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $309.22.

Amgen Price Performance

AMGN opened at $271.66 on Monday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market capitalization of $146.07 billion, a PE ratio of 35.98, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The stock’s 50 day moving average price is $285.94 and its 200-day moving average price is $285.86. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.96 EPS.

Hedge Funds Weigh In On Amgen

Several large investors have recently made changes to their positions in the business. Mattson Financial Services LLC lifted its stake in Amgen by 16.6% in the 1st quarter. Mattson Financial Services LLC now owns 3,247 shares of the medical research company’s stock worth $1,012,000 after purchasing an additional 463 shares in the last quarter. WBI Investments LLC bought a new stake in shares of Amgen in the first quarter worth about $1,007,000. Westbourne Investments Inc. lifted its position in shares of Amgen by 5.5% in the first quarter. Westbourne Investments Inc. now owns 1,925 shares of the medical research company’s stock worth $600,000 after buying an additional 100 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Amgen by 174.3% during the first quarter. Acadian Asset Management LLC now owns 20,328 shares of the medical research company’s stock valued at $6,329,000 after buying an additional 12,918 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Amgen by 9.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 8,065 shares of the medical research company’s stock worth $2,513,000 after acquiring an additional 669 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. Amgen’s payout ratio is currently 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.